August 7, 2002

News Release: WDI Smart Check Selected for World Health Organization - Malaria Program

World Diagnostics, Inc. (WDGI OTC-BB), a rapidly emerging global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that its Smart Check MalariaTest received a perfect score of 100% sensitivity and specificity, thereby qualifying for the "Roll Back Malaria" program which has been accelerated by the World Health Organization (W.H.O.) to address the growing Malaria crisis that grips Southern Africa each fall during the rainy season commencing in October. WDI's Smart Check Malaria Test has now been approved by W.H.O. based on studies completed in June 2002 in Harare, Zimbabwe, W.H.O. headquarters for this project. Additional studies were conducted in Zambia, Mozambique, Angola, and Uganda. The W.H.O. contract is due to start in the fall of 2002, to coincide with the Rift Valley rainy season in Southern Africa. This area comprises the countries named above, with a total population of almost 120 million people. Malaria rates of infection during the rainy season are endemic for three to four months. Management of inventory will be handled by Plaza Diagnostics, WDI's distributor in Zimbabwe.

"The expected volume of screening devices is forecasted to be in excess of 500,000 tests this fall. WDI will definitely be a significant supplier in the program and, while we cannot predict what this could mean in revenues, it is likely that WDI will become a primary supplier for this program," said Basil Psarros, Managing Director for Plaza Diagnostics.

The "Roll Back Malaria" project is an effort to provide more cost effective health care to regions affected seasonally by Malaria outbreaks. Many medical disorders at this time of the year often exhibit symptoms similar to Malaria. W.H.O. believes the expense of each patient treatment, approximately $10 USD, could be reserved for persons truly infected with Malaria by screening for non-Malaria infected persons via a rapid diagnostic device at a cost of $1.00 USD. Such testing could save hundreds of thousands of dollars thereby expanding existing current budgets.

About World Diagnostics, Inc. and GLOBALeMED.com

WDI is an innovative leader in providing a wide range of medical diagnostic and laboratory products worldwide, offering the most comprehensive resource for most medical diagnostic tests and laboratory products on a global basis. WDI provides a network of conventional and dedicated distribution channels for accessing international markets, and a simplified option, through its GLOBALeMED e-commerce platform, for purchasing medical laboratory and healthcare products online.

WDI's marketing platform of distributors and GLOBALeMED partners cover 85 countries, affording professional users easy and unlimited access to critical technical data and information, training aids and online customer support. It is among the most comprehensive resources available for most medical diagnostic tests and laboratory products, currently comprising about 1,000 WDI-branded and numerous other products sold through distributors and directly to medical professionals, hospitals, physician offices, clinical laboratories, and retail drug stores. WDI's GLOBALeMED website is the only multi-cultural, multi-lingual, medical information-based website of its kind, generating new business leads daily and convenient transactional options, through conventional distribution or e-commerce options and contributing to WDI's growing worldwide customer base and name recognition.

WDI's vision is to be the premier resource for supplying diagnostic tests and allied medical laboratory products for the $5 billion emerging nation global marketplace. WDI is aggressively expanding its business and brand name through its distribution network and its GLOBALeMED e-commerce platform, which can be accessed at either www.worlddiagnostics.com or www.globalemed.com. WDI's GLOBALeMED website is the leading multi-cultural, multilingual, medical information-based website delivering efficient access to modern medical technology on a cost-effective basis. WDI has built substantial inroads and assets in the form of licenses and registrations for its products in numerous countries.

Except for historical matters contained herein, the matters discussed in this press release are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the assumptions and involve risk and uncertainties, which may affect World Diagnostics, Inc.'s business and prospects and cause actual results to differ materially from these forward-looking statements.

TEL: 310/234-9535 World Diagnostics, Inc., Barry Peters
EMAIL: This email address is being protected from spambots. You need JavaScript enabled to view it.

WEBSITE This email address is being protected from spambots. You need JavaScript enabled to view it.